文献速递心脑血管急症重症综合管理与镇静镇痛

基因工程猪心脏异种移植同情用药中的移植物功能障碍:一例病例报告

Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report.
PubMed 文献 · Lancet · 2023-06-29
一句话结论首例基因工程猪心脏异种移植术后47天出现舒张性心力衰竭,活检提示抗体介导的内皮损伤、IVIG与供体内皮结合及PCMV/PRV再激活可能参与移植物功能障碍。

2022年1月7日,一名57岁终末期心力衰竭、依赖静脉-动脉体外膜氧合、不适合同种异体移植的男性患者接受了基因工程猪心脏异种移植。术后移植物功能良好,直至术后第47天发生舒张性心力衰竭。术后第50天心内膜心肌活检显示毛细血管损伤、间质水肿、红细胞外渗、罕见血栓性微血管病和补体沉积;术后第56天活检显示纤维化改变。尸检单细胞RNA测序显示重叠病因。作者认为超急性排斥反应被避免,并识别出抗体介导排斥、IVIG与供体内皮强结合可能引起免疫激活、潜伏PCMV/PRV再激活和复制可能启动损伤性炎症反应等潜在介质。

要点

  • 57岁男性终末期心力衰竭患者,依赖静脉-动脉体外膜氧合,不适合同种异体移植,于2022年1月7日接受基因工程猪心脏异种移植。
  • 术后移植物在超声心动图上功能良好,维持心血管及其他器官系统功能直至术后第47天发生舒张性心力衰竭。
  • 术后第50天心内膜心肌活检显示毛细血管损伤伴间质水肿、红细胞外渗、罕见血栓性微血管病和补体沉积。
  • 因低丙种球蛋白血症给予静脉注射免疫球蛋白(IVIG)后及首次血浆置换期间,检测到抗猪异种抗体(主要为IgG)升高。
  • 微生物游离DNA检测显示PCMV/PRV游离DNA滴度升高;尸检单细胞RNA测序显示重叠病因。

适用人群与场景

  • 非行走的57岁男性终末期心力衰竭患者,依赖静脉-动脉体外膜氧合支持,不适合同种异体移植,接受基因工程猪心脏异种移植。

处置流程与药物剂量

  • 因低丙种球蛋白血症给予静脉注射免疫球蛋白(IVIG)。
  • 进行首次血浆置换。
  • 在重症监护病房进行广泛临床监测,收集对心脏移植受者护理关键的生理和生化参数。

红旗征与不能漏的情况

  • 术后第47天发生舒张性心力衰竭。
  • 术后第50天心内膜心肌活检显示毛细血管损伤、间质水肿、红细胞外渗、罕见血栓性微血管病和补体沉积。
  • 术后第56天心内膜心肌活检显示纤维化改变,符合进行性心肌僵硬。
  • 微生物游离DNA检测显示PCMV/PRV游离DNA滴度升高。

研究设计与关键结果

  • 病例报告:一例57岁男性终末期心力衰竭患者接受基因工程猪心脏异种移植,术后移植物在超声心动图上功能良好,维持心血管及其他器官系统功能直至术后第47天发生舒张性心力衰竭。
  • 术后第50天心内膜心肌活检显示毛细血管损伤伴间质水肿、红细胞外渗、罕见血栓性微血管病和补体沉积;因低丙种球蛋白血症给予IVIG后及首次血浆置换期间检测到抗猪异种抗体(主要为IgG)升高。
  • 术后第56天心内膜心肌活检显示纤维化改变,符合进行性心肌僵硬;微生物游离DNA检测显示PCMV/PRV游离DNA滴度升高;尸检单细胞RNA测序显示重叠病因。

证据类型、等级与局限

  • 证据类型:病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,广泛内皮损伤提示抗体介导排斥反应。
  • 作者认为,IVIG与供体内皮强结合,可能引起免疫激活。
  • 作者认为,异种移植物中潜伏PCMV/PRV的再激活和复制可能启动损伤性炎症反应。
  • 作者指出,这些发现指向未来改善异种移植结局的具体措施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A genetically engineered pig cardiac xenotransplantation was done on Jan 7, 2022, in a non-ambulatory male patient, aged 57 years, with end-stage heart failure, and on veno-arterial extracorporeal membrane oxygenation support, who was ineligible for an allograft. This report details our current understanding of factors important to the xenotransplantation outcome.

METHODS: Physiological and biochemical parameters critical for the care of all heart transplant recipients were collected in extensive clinical monitoring in an intensive care unit. To ascertain the cause of xenograft dysfunction, we did extensive immunological and histopathological studies, including electron microscopy and quantification of porcine cytomegalovirus or porcine roseolovirus (PCMV/PRV) in the xenograft, recipient cells, and tissue by DNA PCR and RNA transcription. We performed intravenous immunoglobulin (IVIG) binding to donor cells and single-cell RNA sequencing of peripheral blood mononuclear cells.

FINDINGS: After successful xenotransplantation, the graft functioned well on echocardiography and sustained cardiovascular and other organ systems functions until postoperative day 47 when diastolic heart failure occurred. At postoperative day 50, the endomyocardial biopsy revealed damaged capillaries with interstitial oedema, red cell extravasation, rare thrombotic microangiopathy, and complement deposition. Increased anti-pig xenoantibodies, mainly IgG, were detected after IVIG administration for hypogammaglobulinaemia and during the first plasma exchange. Endomyocardial biopsy on postoperative day 56 showed fibrotic changes consistent with progressive myocardial stiffness. Microbial cell-free DNA testing indicated increasing titres of PCMV/PRV cell-free DNA. Post-mortem single-cell RNA sequencing showed overlapping causes.

INTERPRETATION: Hyperacute rejection was avoided. We identified potential mediators of the observed endothelial injury. First, widespread endothelial injury indicates antibody-mediated rejection. Second, IVIG bound strongly to donor endothelium, possibly causing immune activation. Finally, reactivation and replication of latent PCMV/PRV in the xenograft possibly initiated a damaging inflammatory response. The findings point to specific measures to improve xenotransplant outcomes in the future.

FUNDING: The University of Maryland School of Medicine, and the University of Maryland Medical Center.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mohiuddin MM, Singh AK, Scobie L, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. 2023. PMID: 37393920. doi:10.1016/S0140-6736(23)00775-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。